Literature DB >> 25798669

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.

L E Franssen1, N W C J van de Donk2, M E Emmelot3, M W H Roeven4, N Schaap4, H Dolstra5, W Hobo5, H M Lokhorst2, T Mutis3.   

Abstract

Allo-SCT followed by DLIs can establish long-term remissions in multiple myeloma (MM) patients. In many patients, however, the immunotherapeutic graft-versus-tumor (GVT) effect is moderate and not sustained, implying that immune suppression is mediated, among other factors, by regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs). Towards a better understanding and, eventually, manipulation of the immune-regulatory mechanisms in transplanted MM patients, we retrospectively sought a correlation between DLI outcome and circulating CD14(+) MDSCs, CD14(-) MDSCs and Tregs in 53 MM patients before their first DLI. We found significantly elevated frequencies of highly suppressive CD14(+) MDSCs, CD14(-) MDSCs and Tregs in pre-DLI samples from patients. Higher frequencies of Tregs, but not of MDSCs, were significantly associated with non-responsiveness to DLI. Furthermore, a lower frequency of Tregs predicted the development of chronic GVHD, which, in turn, displayed a high association with GVT. Elevated Treg frequencies before DLI were also associated with significantly shorter PFS and OS. Hence, our data reinforce the idea of active suppression of antitumor responses by Tregs in MM patients and therefore suggest that targeting patient Tregs before DLI may improve outcome of DLI.

Entities:  

Mesh:

Year:  2015        PMID: 25798669     DOI: 10.1038/bmt.2015.48

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  37 in total

1.  Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

Authors:  N W C J van de Donk; N Kröger; U Hegenbart; P Corradini; J F San Miguel; H Goldschmidt; J A Perez-Simon; M Zijlmans; R A Raymakers; V Montefusco; F A Ayuk; M H J van Oers; A Nagler; L F Verdonck; H M Lokhorst
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

2.  Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  E Nadal; M Garin; J Kaeda; J Apperley; R Lechler; F Dazzi
Journal:  Leukemia       Date:  2007-01-11       Impact factor: 11.528

3.  Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.

Authors:  D Mougiakakos; R Jitschin; L von Bahr; I Poschke; R Gary; B Sundberg; A Gerbitz; P Ljungman; K Le Blanc
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

4.  Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice.

Authors:  A Luyckx; E Schouppe; O Rutgeerts; C Lenaerts; C Koks; S Fevery; T Devos; D Dierickx; M Waer; J A Van Ginderachter; A D Billiau
Journal:  Bone Marrow Transplant       Date:  2011-10-31       Impact factor: 5.483

5.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.

Authors:  Guliang Xia; Robert L Truitt; Bryon D Johnson
Journal:  Biol Blood Marrow Transplant       Date:  2006-04       Impact factor: 5.742

8.  Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Authors:  Indu R Ramachandran; Anna Martner; Alexandra Pisklakova; Thomas Condamine; Tess Chase; Thomas Vogl; Johannes Roth; Dmitry Gabrilovich; Yulia Nefedova
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  11 in total

Review 1.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

Review 2.  Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

Authors:  Inger S Nijhof; Niels W C J van de Donk; Sonja Zweegman; Henk M Lokhorst
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

Review 3.  Is immunotherapy here to stay in multiple myeloma?

Authors:  Paula Rodríguez-Otero; Bruno Paiva; Monika Engelhardt; Felipe Prósper; Jesús F San Miguel
Journal:  Haematologica       Date:  2017-01-12       Impact factor: 9.941

Review 4.  Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.

Authors:  Daniel E Meyers; Satbir Thakur; Chandini M Thirukkumaran; Don G Morris
Journal:  Blood Cancer J       Date:  2017-12-05       Impact factor: 11.037

5.  Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis.

Authors:  Haimeng Yan; Gaofeng Zheng; Jianwei Qu; Yang Liu; Xi Huang; Enfan Zhang; Zhen Cai
Journal:  J Cell Physiol       Date:  2019-06-18       Impact factor: 6.384

Review 6.  Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance.

Authors:  Lisa C Holthof; Tuna Mutis
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

Review 7.  Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.

Authors:  Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Cesarina Giallongo; Emanuele D'Amico; Aurora Zanghì; Fabrizio Puglisi; Concetta Conticello; Annalisa Chiarenza; Daniele Tibullo; Francesco Di Raimondo; Alessandra Romano
Journal:  Int J Mol Sci       Date:  2019-11-01       Impact factor: 5.923

8.  Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.

Authors:  Liana Nikolaenko; Saurabh Chhabra; Noa Biran; Arnab Chowdhury; Parameswaran N Hari; Amrita Krishnan; Joshua Richter
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-01-27

Review 9.  The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).

Authors:  Christos Demosthenous; Ioanna Sakellari; Vassiliki Douka; Penelope Georgia Papayanni; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 10.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.